XML 85 R55.htm IDEA: XBRL DOCUMENT v3.25.1
Long-Term Investments (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2024
May 24, 2024
Mar. 14, 2024
Long-Term Investments [Line Items]            
Percentage of common stock shares 51.00%          
Aggregate amount     $ 2,688,578      
Prepayment amount     $ 1,895,556      
Converted shares     994,450      
Common stock, shares authorized [1] 100,000,000 100,000,000        
Ordinary shares issued 13,868,484 [1] 7,940,298 [1]       1,610,700
Ordinary shares outstanding [1] 13,868,484 7,940,298        
Payment to joint venture $ 150,000          
Common Stock [Member]            
Long-Term Investments [Line Items]            
Ordinary shares issued       41,387 200,000  
BioFirst Corporation [Member]            
Long-Term Investments [Line Items]            
Percentage of common stock shares 18.68% 18.68%        
Prepayment amount $ 1,124,842          
Ordinary shares issued 3,049          
Ordinary shares outstanding 3,049          
Rgene Corporation [Member]            
Long-Term Investments [Line Items]            
Percentage of common stock shares 26.65% 26.65%        
BioLite Japan K.K. [Member]            
Long-Term Investments [Line Items]            
Percentage of common stock shares 49.00%          
Common stock, shares authorized 10,000          
Payment to joint venture $ 150,000          
Lucidaim Co Ltd [Member] | Common Stock [Member]            
Long-Term Investments [Line Items]            
Owned shares 1,555          
BioLite JP [Member]            
Long-Term Investments [Line Items]            
Owned shares 1,494          
[1] Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.